PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
March 26, 2026The Oncologist0 citationsOpen Access

Homologous Recombination Deficiency and Genomic Alterations in Advanced Prostate Cancer: Insights for Precision Therapy

View Full Paper
CMChiara MercinelliDPDean PavlickNANeeraj Agarwal

Key Points

  • The research aims to understand the genomic landscape associated with homologous recombination deficiency in advanced prostate cancer.
  • Analyzed the genomic features of advanced prostate cancer with BRCA2 loss
  • Assessed homologous recombination deficiency (HRD) characteristics
  • Evaluated the implications for patient selection for PARP inhibitors using comprehensive genomic profiling (CGP)
  • Advanced prostate cancer with BRCA2 loss exhibited distinct genomic alterations
  • Higher sensitivity to PARP inhibitors indicated for BRCA2-loss CAPC
  • Highlighting the importance of HRD signature in clinical decision-making

Abstract

BRCA2-loss CAPC displays a distinct genomic landscape, marked by robust HRD features, suggesting the potential of higher sensitivity to PARPi. These findings highlight the relevance of HRDsig, and routinely use of CGP in refining patient selection for PARPi and guiding the design of future clinical trials.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Mercinelli et al. (2026) studied this question.

synapsesocial.com/papers/69c4cd25fdc3bde448919126https://doi.org/10.1093/oncolo/oyag100
Ask AI
Helpful
Bookmark
Share
View Full Paper